-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Medline, Lowers Price Target to $43

Benzinga·09/25/2026 16:17:03
UBS analyst Kevin Caliendo maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $45 to $43.